Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a sell rating to a hold rating in a report published on Monday.

Several other research firms also recently commented on ATNM. Maxim Group lifted their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, March 19th. HC Wainwright reiterated a buy rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Actinium Pharmaceuticals currently has a consensus rating of Moderate Buy and an average target price of $25.72.

Actinium Pharmaceuticals Stock Up 12.5 %

Shares of ATNM stock opened at $8.75 on Monday. Actinium Pharmaceuticals has a 52 week low of $4.00 and a 52 week high of $9.86. The firm has a market capitalization of $260.58 million, a P/E ratio of -5.12 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The firm had revenue of $0.08 million during the quarter. Sell-side analysts anticipate that Actinium Pharmaceuticals will post -1.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ATNM. Brandywine Global Investment Management LLC acquired a new position in Actinium Pharmaceuticals during the 3rd quarter valued at about $1,033,000. Sanders Morris Harris LLC acquired a new position in shares of Actinium Pharmaceuticals in the first quarter valued at about $78,000. Finally, Creative Financial Designs Inc. ADV increased its holdings in shares of Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the period. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.